From my understanding, yes, CF33 trial must come first. At the very least, it must be shown to be safe and tolerable. I believe the company is pretty confident of achieving that just like how they have shown the B-cell platform to be safe and tolerable. That is probably why they schedule the combo trial to start early 2022.
Ann: Investor Presentation, page-13
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.001(1.79%) |
Mkt cap ! $416.4M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.5¢ | $923.6K | 16.70M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 4324614 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 3113463 | 18 |
View Market Depth
| Last trade - 12.55pm 06/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |